Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus

Amilcar L. Morales, Luz E. Liriano-Ward, Amber Tierney, Michelle Sang, Alexander Lalos, Mohamed Hassan, Vinay Nair, Thomas Schiano, Rohit Satoskar, Coleman Smith

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Patients with end-stage renal diseases on hemodialysis have a high prevalence of hepatitis C infection (HCV). In most patients, treatment for HCV is delayed until postrenal transplant. We assessed the effectiveness and tolerance of ledipasvir/sofosbuvir (LDV/SOF) in 32 postkidney transplant patients infected with HCV. The group was composed predominantly of treatment-naïve (75%) African American (68.75%) males (75%) infected with genotype 1a (62.5%). Most patients received a deceased donor kidney graft (78.1%). A 96% sustained viral response (SVR) was reported (27/28 patients). One patient relapsed. One patient with baseline graft dysfunction developed borderline rejection. No graft loss was reported. Six HIV-coinfected patients were included in our analysis. Five of these patients achieved SVR 12. There were four deaths, and one of the deaths was in the HIV group. None of the deaths were attributed to therapy. Coinfected patients tolerated therapy well with no serious adverse events. Serum creatinine remained stable at baseline, end of therapy, and last follow-up, (1.351±.50 mg/dL; 1.406±.63 mg/dL; 1.290±.39 mg/dL, respectively). In postkidney transplant patients with HCV infection with or without coinfection with HIV, a combination of LDV/SOF was well tolerated and effective.

Original languageEnglish (US)
Article numbere12941
JournalClinical Transplantation
Volume31
Issue number5
DOIs
StatePublished - May 1 2017
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Hepacivirus
Transplants
HIV
sofosbuvir drug combination ledipasvir
Therapeutics
Hepatitis C
Infection
Coinfection
African Americans
Chronic Kidney Failure
Renal Dialysis
Creatinine
Genotype
Tissue Donors
Kidney

Keywords

  • chronic hepatitis C
  • HIV
  • kidney transplant
  • ledipasvir/sofosbuvir

ASJC Scopus subject areas

  • Transplantation

Cite this

Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus. / Morales, Amilcar L.; Liriano-Ward, Luz E.; Tierney, Amber; Sang, Michelle; Lalos, Alexander; Hassan, Mohamed; Nair, Vinay; Schiano, Thomas; Satoskar, Rohit; Smith, Coleman.

In: Clinical Transplantation, Vol. 31, No. 5, e12941, 01.05.2017.

Research output: Contribution to journalArticle

Morales, AL, Liriano-Ward, LE, Tierney, A, Sang, M, Lalos, A, Hassan, M, Nair, V, Schiano, T, Satoskar, R & Smith, C 2017, 'Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus', Clinical Transplantation, vol. 31, no. 5, e12941. https://doi.org/10.1111/ctr.12941
Morales, Amilcar L. ; Liriano-Ward, Luz E. ; Tierney, Amber ; Sang, Michelle ; Lalos, Alexander ; Hassan, Mohamed ; Nair, Vinay ; Schiano, Thomas ; Satoskar, Rohit ; Smith, Coleman. / Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus. In: Clinical Transplantation. 2017 ; Vol. 31, No. 5.
@article{3e7e41669eeb4501a34d6823a107a5bf,
title = "Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus",
abstract = "Patients with end-stage renal diseases on hemodialysis have a high prevalence of hepatitis C infection (HCV). In most patients, treatment for HCV is delayed until postrenal transplant. We assessed the effectiveness and tolerance of ledipasvir/sofosbuvir (LDV/SOF) in 32 postkidney transplant patients infected with HCV. The group was composed predominantly of treatment-na{\"i}ve (75{\%}) African American (68.75{\%}) males (75{\%}) infected with genotype 1a (62.5{\%}). Most patients received a deceased donor kidney graft (78.1{\%}). A 96{\%} sustained viral response (SVR) was reported (27/28 patients). One patient relapsed. One patient with baseline graft dysfunction developed borderline rejection. No graft loss was reported. Six HIV-coinfected patients were included in our analysis. Five of these patients achieved SVR 12. There were four deaths, and one of the deaths was in the HIV group. None of the deaths were attributed to therapy. Coinfected patients tolerated therapy well with no serious adverse events. Serum creatinine remained stable at baseline, end of therapy, and last follow-up, (1.351±.50 mg/dL; 1.406±.63 mg/dL; 1.290±.39 mg/dL, respectively). In postkidney transplant patients with HCV infection with or without coinfection with HIV, a combination of LDV/SOF was well tolerated and effective.",
keywords = "chronic hepatitis C, HIV, kidney transplant, ledipasvir/sofosbuvir",
author = "Morales, {Amilcar L.} and Liriano-Ward, {Luz E.} and Amber Tierney and Michelle Sang and Alexander Lalos and Mohamed Hassan and Vinay Nair and Thomas Schiano and Rohit Satoskar and Coleman Smith",
year = "2017",
month = "5",
day = "1",
doi = "10.1111/ctr.12941",
language = "English (US)",
volume = "31",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus

AU - Morales, Amilcar L.

AU - Liriano-Ward, Luz E.

AU - Tierney, Amber

AU - Sang, Michelle

AU - Lalos, Alexander

AU - Hassan, Mohamed

AU - Nair, Vinay

AU - Schiano, Thomas

AU - Satoskar, Rohit

AU - Smith, Coleman

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Patients with end-stage renal diseases on hemodialysis have a high prevalence of hepatitis C infection (HCV). In most patients, treatment for HCV is delayed until postrenal transplant. We assessed the effectiveness and tolerance of ledipasvir/sofosbuvir (LDV/SOF) in 32 postkidney transplant patients infected with HCV. The group was composed predominantly of treatment-naïve (75%) African American (68.75%) males (75%) infected with genotype 1a (62.5%). Most patients received a deceased donor kidney graft (78.1%). A 96% sustained viral response (SVR) was reported (27/28 patients). One patient relapsed. One patient with baseline graft dysfunction developed borderline rejection. No graft loss was reported. Six HIV-coinfected patients were included in our analysis. Five of these patients achieved SVR 12. There were four deaths, and one of the deaths was in the HIV group. None of the deaths were attributed to therapy. Coinfected patients tolerated therapy well with no serious adverse events. Serum creatinine remained stable at baseline, end of therapy, and last follow-up, (1.351±.50 mg/dL; 1.406±.63 mg/dL; 1.290±.39 mg/dL, respectively). In postkidney transplant patients with HCV infection with or without coinfection with HIV, a combination of LDV/SOF was well tolerated and effective.

AB - Patients with end-stage renal diseases on hemodialysis have a high prevalence of hepatitis C infection (HCV). In most patients, treatment for HCV is delayed until postrenal transplant. We assessed the effectiveness and tolerance of ledipasvir/sofosbuvir (LDV/SOF) in 32 postkidney transplant patients infected with HCV. The group was composed predominantly of treatment-naïve (75%) African American (68.75%) males (75%) infected with genotype 1a (62.5%). Most patients received a deceased donor kidney graft (78.1%). A 96% sustained viral response (SVR) was reported (27/28 patients). One patient relapsed. One patient with baseline graft dysfunction developed borderline rejection. No graft loss was reported. Six HIV-coinfected patients were included in our analysis. Five of these patients achieved SVR 12. There were four deaths, and one of the deaths was in the HIV group. None of the deaths were attributed to therapy. Coinfected patients tolerated therapy well with no serious adverse events. Serum creatinine remained stable at baseline, end of therapy, and last follow-up, (1.351±.50 mg/dL; 1.406±.63 mg/dL; 1.290±.39 mg/dL, respectively). In postkidney transplant patients with HCV infection with or without coinfection with HIV, a combination of LDV/SOF was well tolerated and effective.

KW - chronic hepatitis C

KW - HIV

KW - kidney transplant

KW - ledipasvir/sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=85016299780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016299780&partnerID=8YFLogxK

U2 - 10.1111/ctr.12941

DO - 10.1111/ctr.12941

M3 - Article

VL - 31

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 5

M1 - e12941

ER -